Exicure Inc: Rises on positive results from skin cancer drug trial
16/09/2020 13:32
** Shares of biotechnology firm XCUR.O jump ~9% premarket
to $2.19, their highest level in nearly three weeks
** Co says its cavrotolimod treatment, being tested for the
treatment of skin cancer, showed positive interim results in its
ongoing phase 1b trial, with target tumor shrinkage observed in
37% of patients urn:newsml:reuters.com:*:nBw3sms88a
** XCUR says phase 2 arm of the trial is currently
recruiting, expects to provide interim overall response rate
results by H1 2021
** Stock set for best day since mid-June; Down 29.7% YTD
(Reporting by Ambar Warrick in Bengaluru)
((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net;
Twitter: @AmbarWarrick))
Recent news on Exicure
See all newsBrief: Exicure Announces 1-For-5 Reverse Stock Split
U.S. STOCKS ON THE MOVE-MercadoLibre, DoorDash, Coinbase
Brief: Exicure Inc Says Received Nasdaq Delinquency Notice On Late Filing Of Its Form 10-K
Brief: Exicure And Bluejay Therapeutics Enter Into A Patent License Agreement To Develop Cavrotolimod For The Treatment Of Hepatitis
Brief: Exicure Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq